• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    V

    Velindre NHS Trust

    EST. 1994
    797论文总数
    4万引用总数

    .

    论文量&引用量时间轴

    机构学者

    论文(797)

    年份
    起
    –
    止
    排序
    1193 National Contouring Workshop for Lung SABR
    Iain Phillips,Ceri Powell,Patricia Diez,Fiona McDonald
    2026LUNG CANCER(2026)
    引用
    AI阅读
    加入学术空间
    2Releasing Capacity in Hospital Clinics by Enabling People with Haemochromatosis to Donate Blood in Wales
    Stephanie Ditcham, Joanne Gregory, Alison Roberts, Edwin Massey
    2026BRITISH JOURNAL OF HAEMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    3SCOPE, A Phase 2 Clinical Trial with Off-the-shelf DNA Plasmid Vaccine in First Line Advanced Melanoma Combined with Check Point Blockade, Shows Good T Cell Responses Which Correlate with Long Progression Free Survival
    Joseph Chadwick,Samantha Paston,Kate Young,Heather Shaw,Pippa Corrie,Sarah Danson,Miranda Payne,Poulam Patel,Maria Marples,Ioannis Karydis,Satish Kumar, Clare Barlow,
    2026CANCER RESEARCH(2026)
    引用
    AI阅读
    加入学术空间
    4A Phase II Trial of Mtorc1/2 Inhibition in STK11 Deficient Non Small Cell Lung Cancer
    Gary Middleton, Helen L Robbins, Peter Fletcher,Joshua Savage, Manita Mehmi,Yvonne Summers,Alastair Greystoke,Nicola Steele,Sanjay Popat,Pooja Jain,James Spicer,Judith Cave,

    There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2 inhibition. In arm B2 of the National Lung Matrix Trial 54 patients with NSCLC received vistusertib, of which 49 were STK11-deficient (30 with KRAS mutation (B2D), 19 without (B2S)). Objective response (OR) and durable clinical benefit (DCB) rates with 95% credible intervals (CrI) were estimated from posterior probability distributions generated using Bayesian beta-binomial conjugate analysis. In B2D, 2 per-protocol patients obtained OR (estimated true OR rate (95%CrI) 9.8% (2.4–24.3). Estimates of true DCB rate (95%CrI): B2D 24.4% (11.1–42.3), B2S 14.6% (3.6–34.7). Overall, vistusertib cannot be recommended in this context. Longitudinal ctDNA analysis demonstrates enrichment of SMARCA4 mutations post-treatment. In vitro studies show adaptive resistance to mTORC1/2 inhibition via AKT reactivation. (NCT02664935, ISRCTN38344105, EudraCT 2014-000814-73, 10 June 2015)

    2025NPJ precision oncology(2025)引用:5
    引用
    AI阅读
    加入学术空间
    5Endovascular Solutions for Abdominal Aortic Aneurysms: Fenestrated, Branched and Custom-Made Devices.
    Kofi Cox,Ho Cheung Anthony Yip,Alexander Geragotellis,Mohammed Al-Tawil,Matti Jubouri,Ian M. Williams,Mohamad Bashir

    Background Abdominal aortic aneurysm (AAA) has a prevalence of 4.8%. AAA rupture is associated with significant mortality, thus surgical intervention is generally required once the aneurysm diameter exceeds 5.5 cm. Endovascular aneurysm repair (EVAR) is the predominant repair modality for AAA. However, in patients with complex aortic anatomy, fenestrated or branched EVAR is a superior repair option vs standard EVAR. Fenestrated and branched endoprostheses can be off-the-shelf or custom-made, which offers a more individualised approach. Aim To summarise and evaluate the clinical outcomes achieved by fenestrated EVAR (FEVAR) and branched EVAR (BEVAR), and to explore the role of custom-made endoprostheses in contemporary AAA management. Methods A literature search using Ovid Medline and Google Scholar was conducted to identify literature pertaining to the use and outcomes of fenestrated, branched, fenestrated-branched and custom-made endoprostheses for AAA repair. Results FEVAR is an effective repair modality for patients with AAA that offers similar early survival, improved early morbidity but higher rates of reintervention in comparison to open surgical repair (OSR). Compared with standard EVAR, FEVAR is associated with similar in-hospital mortality yet higher rates of morbidity, especially regarding renal outcomes. BEVAR outcomes are rarely reported exclusively in the context of AAA repair. When reported, BEVAR is an acceptable alternative to EVAR in the treatment of complex aortic aneurysms and has similar reported complication issues to FEVAR. Custom-made grafts are a good alternative treatment option for complex aneurysms where hostile aneurysm anatomy precludes the use of conventional EVAR and sufficient time is available for the manufacturing of such devices. Conclusion FEVAR offers a very effective treatment for patients with complex aortic anatomy and has been well-characterised over the past decade. RCTs and longer-term studies are desirable for unbiased comparison of non-standard EVAR modalities.

    2025VASCULAR AND ENDOVASCULAR SURGERY(2025)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 797 篇论文

    合作机构(100)

    卡迪夫大学合作论文 130
    威尔士大学医院合作论文 45
    皇家马斯登医院合作论文 41
    皇家马斯登 NHS 基金会信托合作论文 32
    牛津大学合作论文 30
    Beatson West of Scotland Cancer Centre合作论文 29
    韦斯顿公园医院合作论文 26
    利兹大学合作论文 23
    曼彻斯特大学合作论文 22
    伯明翰大学合作论文 21

    机构统计